UA42706C2 - Полімерний кон'югат камптотецину, фармацевтична композиція - Google Patents

Полімерний кон'югат камптотецину, фармацевтична композиція

Info

Publication number
UA42706C2
UA42706C2 UA95073111A UA95073111A UA42706C2 UA 42706 C2 UA42706 C2 UA 42706C2 UA 95073111 A UA95073111 A UA 95073111A UA 95073111 A UA95073111 A UA 95073111A UA 42706 C2 UA42706 C2 UA 42706C2
Authority
UA
Ukraine
Prior art keywords
phe
leu
gly
polymer
camptothecin derivatives
Prior art date
Application number
UA95073111A
Other languages
English (en)
Russian (ru)
Inventor
Франческо Анджелуччі
Франческо Анджелуччи
Антоніо СУАРАТО
Антонио Суарато
Original Assignee
Фармація С.П.А.
Фармация С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармація С.П.А., Фармация С.п.А. filed Critical Фармація С.П.А.
Publication of UA42706C2 publication Critical patent/UA42706C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Кон’югат містить просторову групу [spA], що вибирають з: Ala-Gly, Phe-Gly, Phe-Phe, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Phe-Gly, и Phe-Leu-Gly-Phe.
UA95073111A 1993-10-08 1994-09-21 Полімерний кон'югат камптотецину, фармацевтична композиція UA42706C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
PCT/EP1994/003154 WO1995010304A1 (en) 1993-10-08 1994-09-21 Polymer-bound camptothecin derivatives

Publications (1)

Publication Number Publication Date
UA42706C2 true UA42706C2 (uk) 2001-11-15

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95073111A UA42706C2 (uk) 1993-10-08 1994-09-21 Полімерний кон'югат камптотецину, фармацевтична композиція

Country Status (24)

Country Link
US (1) US5773522A (uk)
EP (1) EP0673258B1 (uk)
JP (1) JPH08504217A (uk)
KR (1) KR100359005B1 (uk)
CN (1) CN1138565C (uk)
AT (1) ATE239507T1 (uk)
AU (1) AU679788B2 (uk)
CA (1) CA2150132A1 (uk)
DE (1) DE69432627T2 (uk)
DK (1) DK0673258T3 (uk)
ES (1) ES2198421T3 (uk)
FI (1) FI952746A0 (uk)
GB (1) GB9320781D0 (uk)
HU (1) HU215588B (uk)
IL (1) IL111173A (uk)
MY (1) MY116624A (uk)
NZ (1) NZ273952A (uk)
PL (1) PL178132B1 (uk)
PT (1) PT673258E (uk)
RU (1) RU2149646C1 (uk)
TW (1) TW316905B (uk)
UA (1) UA42706C2 (uk)
WO (1) WO1995010304A1 (uk)
ZA (1) ZA947823B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998014459A1 (de) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
DK2984085T3 (da) 2013-04-10 2019-10-21 Syndevrx Inc Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme
WO2015029615A1 (ja) * 2013-08-26 2015-03-05 独立行政法人科学技術振興機構 接着剤
KR20180093995A (ko) 2015-12-10 2018-08-22 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
US10646463B2 (en) 2016-01-11 2020-05-12 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
IL111173A (en) 1998-10-30
HUT71678A (en) 1996-01-29
GB9320781D0 (en) 1993-12-01
PL309328A1 (en) 1995-10-02
RU95112841A (ru) 1997-06-27
EP0673258A1 (en) 1995-09-27
CN1115564A (zh) 1996-01-24
FI952746A (fi) 1995-06-05
WO1995010304A1 (en) 1995-04-20
DE69432627D1 (en) 2003-06-12
MY116624A (en) 2004-03-31
CA2150132A1 (en) 1995-04-20
RU2149646C1 (ru) 2000-05-27
HU9502084D0 (en) 1995-09-28
AU679788B2 (en) 1997-07-10
ZA947823B (en) 1995-07-03
FI952746A0 (fi) 1995-06-05
US5773522A (en) 1998-06-30
ES2198421T3 (es) 2004-02-01
NZ273952A (en) 1996-10-28
DK0673258T3 (da) 2003-08-25
HU215588B (hu) 1999-01-28
PT673258E (pt) 2003-09-30
JPH08504217A (ja) 1996-05-07
PL178132B1 (pl) 2000-03-31
AU7783694A (en) 1995-05-04
KR100359005B1 (ko) 2003-04-26
DE69432627T2 (de) 2004-03-25
TW316905B (uk) 1997-10-01
EP0673258B1 (en) 2003-05-07
ATE239507T1 (de) 2003-05-15
CN1138565C (zh) 2004-02-18
IL111173A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
UA42706C2 (uk) Полімерний кон'югат камптотецину, фармацевтична композиція
WO1999033522A3 (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancer
TW370532B (en) The use of cetrorelix and other nona and decapeptides in the preparation of a medicament for combating AIDS and for growth stimulation
WO1998002454A3 (en) Conjugates of soluble peptidic compounds with membrane-binding agents
AU5536196A (en) Cancer diagnosis and therapy based on mutations in tgf-beta receptors
HUP9801817A3 (en) Dolastatin derivatives, their preparation and use
AU3705889A (en) Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
AP9801392A0 (en) Concentrated antibody preparation.
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU3769297A (en) Dolastatin pentapeptide derivatives and their use as antitumor agents
AU8918998A (en) Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
EP0830357A4 (en) RADIOSENSITIZING DIAMINES AND PHARMACEUTICAL PREPARATIONS THEREOF
AU8487191A (en) 2-aminopyrimidine-4-caroxamide derivatives, their preparation and their use in therapy
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
HK1019606A1 (en) Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
MY137303A (en) Methods for treating proliferative diseases
AU5652096A (en) Azacycloalcane derivatives, their preparation and their applications in therapy
SI1000063T1 (en) 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO(4,5-b)INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
AU6128896A (en) Isoindole derivatives, their preparation and their application in therapy
AU4119397A (en) Novel combination preparations and their use in immunodiagnosis and immunotherapy
AU3991899A (en) Verotoxin b subunit for immunization
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
AU1507992A (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their application in therapy
AU4463897A (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
HRP960117B1 (en) Bicyclic compounds, their preparation and use in pharmaceutical preparations